Eli Lilly and Company completes $1.4bn acquisition of POINT Biopharma
Eli Lilly and Company (NYSE: LLY) has announced the successful completion of its $1.4 billion acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a notable ... Read More
Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in ... Read More
Lilly gets Jaypirca FDA approval for mantle cell lymphoma
Loxo@Lilly, the oncology division of Eli Lilly and Company (Lilly), has secured the accelerated approval of the US Food and Drug Administration (FDA) for Jaypirca ... Read More